Insider Selling: Bausch + Lomb (NYSE:BLCO) CAO Sells $2,294,067.20 in Stock

Bausch + Lomb Corporation (NYSE:BLCO) CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $20.48, for a total value of $2,294,067.20. Following the completion of the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at $938,618.88. This trade represents a 70.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Frederick Munsch also recently made the following trade(s):

• On Monday, August 10th, Frederick Munsch sold 52,900 shares of Bausch + Lomb stock. The stock was sold at an average price of $16.78, for a total value of $887,662.00.

Bausch + Lomb Price Performance

Shares of Bausch + Lomb stock opened at $20.59 on Thursday. The stock has a 50 day moving average of $17.53 and a 200 day moving average of $16.73. Bausch + Lomb Corporation has a 12 month low of $14.44 and a 12 month high of $21.36. The firm has a market cap of $7.36 billion, a PE ratio of -66.42, a PEG ratio of 0.53 and a beta of 0.52. The company has a current ratio of 1.56, a quick ratio of 1.04 and a debt-to-equity ratio of 0.78.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.13. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The business had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same quarter last year, the business posted $0.18 EPS. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, research analysts expect that Bausch + Lomb Corporation will post 0.94 EPS for the current fiscal year.

Analyst Ratings Changes

BLCO has been the topic of several research reports. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research report on Tuesday, September 15th. Zacks Research raised shares of Bausch + Lomb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Wall Street Zen upgraded shares of Bausch + Lomb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 31st. Citigroup lifted their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Finally, Leerink Partners initiated coverage on shares of Bausch + Lomb in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $24.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.83.

Institutional Investors Weigh In On Bausch + Lomb

Several institutional investors have recently modified their holdings of BLCO. State of Wyoming boosted its holdings in shares of Bausch + Lomb by 6.9% in the 3rd quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after purchasing an additional 887 shares during the period. Beach Point Capital Management LP purchased a new stake in Bausch + Lomb during the 3rd quarter valued at $5,882,000. Counterpoint Mutual Funds LLC purchased a new stake in Bausch + Lomb during the 3rd quarter valued at $670,000. Roxbury Financial LLC purchased a new stake in Bausch + Lomb during the 3rd quarter valued at $33,000. Finally, Engineers Gate Manager LP bought a new stake in Bausch + Lomb in the second quarter worth $1,479,000. 11.07% of the stock is owned by institutional investors.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Growth and debt reduction: Recent results showed revenue up 8% on a constant-currency basis to $1.375 billion, while the company’s net leverage ratio declined to 4.1 times from 5.7 times. Earnings also beat consensus, supporting the positive outlook. Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Higher earnings forecasts: HC Wainwright raised several quarterly estimates and lifted its 2027 EPS forecast to $1.05 from $0.89. Upward estimate revisions can support investor expectations for future growth. Bausch + Lomb analyst estimates
• Positive Sentiment: Momentum and estimate revisions: Zacks said improving earnings estimates could help the shares continue higher in the near term, adding to positive momentum. Why Bausch + Lomb Might Be Well Poised for a Surge
• Neutral Sentiment: Cautious analyst rating: HC Wainwright’s rating was lowered to Neutral, despite its higher earnings forecasts and $22 price target, tempering the otherwise constructive analyst outlook. Bausch + Lomb Stock Rating Lowered by HC Wainwright
• Negative Sentiment: Large insider sale: Chief Accounting Officer Frederick Munsch sold 112,015 shares for about $2.29 million, cutting his holdings by roughly 71%. The sale may raise investor concern, though insider transactions do not necessarily signal a change in business outlook. Bausch + Lomb CAO Sells Shares

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.